When MRSA is everywhere, you need a test for everyone.Screen more patients on more shifts in more hospitals with Spectra™ MRSA. This selective chromogenic medium enables the detection of MRSA colonization to aid in the prevention and control of MRSA in healthcare settings. The test is performed with nasal specimens from patients and healthcare workers to screen for MRSA colonization.

Reliable Proven Performance • Highest PPV (Positive Predictive Value) available for MRSA screening • Differentiates between methicillin-resistant Staphylococcus aureus, Staphylococcus cohnii, and methicillin-resistant Staphylococcus epidermidis through the intensity of the color reaction

Workflow Simplicity • Conclusive results in 24 hours with NO confirmatory testing required • No special handling due to light sensitivity Economical Solution • High PPV decreases hospital and patient costs associated with false positives • Active surveillance is now affordable

Spectra™ MRSA You need a test for everyone.

To aggressively address the rising MRSA epidemic, you need a reliable partner to help you respond efficiently and economically to the challenge.

Once colonized with MRSA, 30-50% of patients become infected1,2

Reported Clinical Performance

MRSA 95.4%

Non-MRSA 99.7%

Agreement 99.1%

Positive Predictive Value (PPV) 98.1%

Negative Predictive Value (NPV) 99.2%

Description Packaging Ref

Spectra™ MRSA 10 Plates/Pk R01821

100 Plates/Cs R01822

Staphaurex® Test Kit 120 Tests/Kit R30859901

400 Tests/Kit R30859902

Coagulase Plasma 5ml/Vial R21050

6 x 5 ml/Vial R21060

PBP2’ Latex Agglutination Test (Oxoid) 50 Tests/Kit DR0900A

Methicillin-Resistant Staphylococcus aureus (MRSA) prevalence rate is increasing• APIC (Association for Professionals in Infection Control and Epidemiology) reports that 46.3 of every 1,000 patients in the U.S. healthcare system are infected or colonized with MRSA3

• Rates are 8 to 11 times greater than previous estimates3

MRSA associated costs are significant to both healthcare providers and patients• MRSA costs U.S. hospitals $3.2 to $4.2 billion annually4

• Direct medical costs range from $27,083 to $34,900 per case4

• Patients with MRSA spend up to 10 days longer in the hospital than those with methicillin-sensitive Staphylococcus aureus infections4

Active surveillance culture programs are an important tool for the control and prevention of MRSA

• Screening must be timely, affordable, and reliable• Active surveillance programs expedite implementation of enhanced infection control measures• Once colonized with MRSA, 30-50% of patients typically become infected1,2

Spectra™ MRSA Chromogenic Media

12076 Santa Fe Drive

Lenexa, KS 66215

991-030

800-255-6730

remel.com

References:1. Hall G., and D. Flayhart. Infection Control Today; February 2006. 2. Klevens, R.M. et. al. Clinical Infectious Disease 2006; 42:389-91. 3. Jarvis, W.R., et. al. American Journal of Infection Control; 2007; 35(10):631-37. 4. U.S. Outcomes Research Group of Pfizer Inc. Presented at the International Society for Pharmacoeconomics Outcome Research Meeting 2005.

To learn more about Healthcare-Associated Infection solutions from Remel, and to see how the MRSA Screening Cost Analyzer can help you understand how to reduce unnecessary isolation costs, visit www.remel.com/hai or contact your Remel Technical Sales Representative.

*Patent pending